Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608238 · ClinicalTrials.gov registry record · Phase 2
The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma
A Phase 2 study of Nodular Basal Cell Carcinoma, sponsored by SkinJect.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT06608238: Recruiting Phase 2 study of Nodular Basal Cell Carcinoma, sponsored by SkinJect.
NCT06608238 is a Phase 2 study of Nodular Basal Cell Carcinoma that is actively recruiting participants, run by SkinJect. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06608238, a Phase 2 study of Nodular Basal Cell Carcinoma, is actively recruiting participants, sponsored by SkinJect.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of the study is to learn about the safety and how effective two different strengths of D-MNA compared to a placebo (a look-alike substance that contains no drug) in the treatment of nodular basal cell skin cancer
Primary Outcome
Proportion of subjects with complete histological clearance of the Target Lesion at Visit 5/EV. Histological clearance represents pathological confirmation of treatment response and is interpreted in the context of overall clinical and histological outcomes.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG D-MNA 200 mcg
- DRUG D-MNA 100 mcg
Study Locations (6)
California
- Site #4 - Fresno
- Site #6 - San Diego
Illinois
- Site #1 - Rolling Meadows
Louisiana
- Site #5 - Mandeville
New Jersey
- Site #3 - Highlands
Tennessee
- Site#2 - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2025-06-02 |
| Phase | Phase 2 |
What NCT06608238 shows while recruiting
NCT06608238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Nodular Basal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06608238 lists 6 locations in 5 states (California, Illinois, Louisiana).
Frequently Asked Questions
What is clinical trial NCT06608238 about?
NCT06608238 is a clinical study titled "The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma". The goal of the study is to learn about the safety and how effective two different strengths of D-MNA compared to a placebo (a look-alike substance that contains no drug) in the treatment of nodular basal cell skin cancer
What is the current status of trial NCT06608238?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-09-03. Estimated completion is 2025-06-02.
What conditions does trial NCT06608238 study?
This clinical trial studies the following conditions: Nodular Basal Cell Carcinoma.
What interventions are being tested in trial NCT06608238?
The interventions under investigation include: Placebo (OTHER), D-MNA 200 mcg (DRUG), D-MNA 100 mcg (DRUG).
Who is sponsoring clinical trial NCT06608238?
This trial is sponsored by SkinJect, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608238 being conducted?
This trial has 6 study locations across California, Illinois, Louisiana, New Jersey, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nodular Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06608238's enrollment target sits among peer trials
60 1027th of 2000 higher than 869 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI